Luo, Yingying and Xia, Jun and Zhao, Zhan and Chang, Yaping and Bee, Yong Mong and Nguyen, Khue Thy and Lim, Soo and Yabe, Daisuke and McGill, Margaret and Kong, Alice Pik Shan and Chan, Siew Pheng and Deodat, Marisa and Deerochanawong, Chaicharn and Suastika, Ketut and Xu, Chenchen and Chen, Liming and Chen, Wei and Li, Xiaoying and Zhao, Weigang and Yao, Xiaomei and Ji, Linong (2023) Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta-analysis. Journal of Diabetes, 15 (5). pp. 419-435. ISSN 1753-0393, DOI https://doi.org/10.1111/1753-0407.13381.
Full text not available from this repository.Abstract
AimsTo investigate the effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins in insulin-naive patients with type 2 diabetes mellitus. MethodsMEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from January 2000 to February 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was adopted. The registration ID is CRD42022319078 in PROSPERO. ResultsAmong 11 163 citations retrieved, 35 publications met the planned criteria. From meta-analyses and network meta-analyses, we found that when injecting basal insulin regimens at bedtime, the optimal choice in order of most to least effective might be glargine U-300 or degludec U-100, glargine U-100 or detemir, followed by neutral protamine hagedorn (NPH). Injecting glargine U-100 in the morning may be more effective (ie, more patients archiving glycated hemoglobin < 7.0%) and lead to fewer hypoglycemic events than injecting it at bedtime. The optimal starting dose for the initiation of any basal insulins can be 0.10-0.20 U/kg/day. There is no eligible evidence to investigate the optimal maintenance dose for basal insulins. ConclusionsThe five basal insulins are effective for the target population. Glargine U-300, degludec U-100, glargine U-100, and detemir lead to fewer hypoglycemic events than NPH without compromising glycemic control.
Item Type: | Article |
---|---|
Funders: | UNSPECIFIED |
Uncontrolled Keywords: | basal insulin; effectiveness; initiation and maintenance dose; safety; systematic review; type 2 diabetes |
Subjects: | R Medicine > RZ Other systems of medicine |
Divisions: | Universiti Malaya Medical Centre (UMMC) |
Depositing User: | Ms Zaharah Ramly |
Date Deposited: | 12 Jun 2024 00:09 |
Last Modified: | 12 Jun 2024 00:09 |
URI: | http://eprints.um.edu.my/id/eprint/38300 |
Actions (login required)
View Item |